{
    "root": "3119ccae-e688-d870-e063-6394a90a148a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ezetimibe",
    "value": "20250324",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE 2208 (3 MPA.S)",
            "code": "9H4L916OBU"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24"
        }
    ],
    "indications": "ezetimibe tabletsareindicated : combination statin , alone additional low-density lipoprotein cholesterol ( ldl-c ) lowering therapy isnot possible , adjunct diet reduce elevated ldl-c adults primary hyperlipidemia , including heterozygous familial hypercholesterolemia ( hefh ) . combination statin adjunct todiet reduce elevated ldl-c pediatric patients 10 years age older hefh . combination fenofibrate adjunct todiet reduce elevated ldl-c adults mixed hyperlipidemia . combination statin , ldl-c lowering therapies , toreduce elevated ldl-c levels adults pediatric patients 10 years age older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet reduction elevated sitosterol campesterol levels inadults pediatric patients 9 years age older homozygous familial sitosterolemia . ezetimibe tablets used combination statin , fenofibrate , orother ldl-c lowering therapies , refer prescribing information products information safe effective .",
    "contraindications": "recommended dose ezetimibe tablets 10 mg orally daily , administered without food . dose missed , take missed dose assoon possible . double next dose . assess ldl-c clinically appropriate , early as4 weeks initiating ezetimibe tablets . administer ezetimibe tablets atleast 2 hours 4 hours bile acid sequestrant [ ( 7 ) ] .",
    "warningsAndPrecautions": "ezetimibe tablets usp , 10 mg white off-white , capsule shaped beveled edge tablets debossed `` k 31 `` one side plain side . supplied follows : ndc : 70518-3797-00 ndc : 70518-3797-01 packaging : 90 1 bottle plastic packaging : 100 1 bottle plastic storage store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect moisture . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "ezetimibe tablets contraindicated patients known hypersensitivity ezetimibe excipients ezetimibe tablets . hypersensitivity including anaphylaxis , angioedema , rash , urticaria reported [ ( 6.2 ) ] . used combination statin , fenofibrate , ldl-c lowering therapy , ezetimibe tablets contraindicated patients statin , fenofibrate , ldl-c lowering therapy contraindicated . refer tothe prescribing information products list [ ( 5.1 ) ] .",
    "indications_original": "Ezetimibe tabletsareindicated:\n                  \n                  \n                     \n                        In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy isnot possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).\n                     \n                     \n                        In combination with a statin as an adjunct todiet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.\n                     \n                     \n                        In combination with fenofibrate as an adjunct todiet to reduce elevated LDL-C in adults with mixed hyperlipidemia.\n                     \n                     \n                        In combination with a statin, and other LDL-C lowering therapies, toreduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).\n                     \n                     \n                        As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels inadults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.\n                     \n                  \n                  \n                     When ezetimibe tablets are used in combination with a statin, fenofibrate, orother LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.",
    "contraindications_original": "The recommended dose of ezetimibe tablets is 10 mg orally once daily, administered with or without food.\n                     \n                        If as dose is missed, take the missed dose assoon as possible. Do not double the next dose.\n                     \n                     \n                        Assess LDL-C when clinically appropriate, as early as4 weeks after initiating ezetimibe tablets.\n                     \n                     \n                        Administer ezetimibe tablets atleast 2 hours before or 4 hours after administration of a bile acid sequestrant \n  \n    [see \n   \n     Drug Interactions (7)]\n  \n    .",
    "warningsAndPrecautions_original": "Ezetimibe Tablets USP, 10 mg white to off-white, capsule shaped beveled edge tablets debossed with \"K 31\" on one side and plain on other side. They are supplied as follows:\n                  \n                  NDC: 70518-3797-00\n                  NDC: 70518-3797-01\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 100 in 1 BOTTLE PLASTIC\n                  \n                  Storage\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Ezetimibe tablets are contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported \n \n  [see \n  \n   Adverse Reactions (6.2)]\n \n  .\n\n \n                  \n                  \n                     When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets are contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer tothe Prescribing Information of these products for a list of their contraindications \n \n   [see \n  \n    Warnings and Precautions (5.1)]\n \n   ."
}